Related Experiment Video
Updated: Jul 11, 2025
07:23
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
352
Synthetic Reader-Actuators Targeted to Polycomb-Silenced Genes Block Triple-Negative Breast Cancer Proliferation and
Lauren Hong1, Natecia L Williams2, Maya Jaffe1
1Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA; and Emory University, Atlanta, Georgia, USA.
GEN Biotechnology
|November 6, 2023
Summary
Scientists developed a synthetic reader-actuator (SRA) to target polycomb chromatin, reactivating tumor suppressor genes. This approach shows promise for treating triple-negative breast cancer (TNBC) by inhibiting cancer proliferation and invasion.
Area of Science:
- Epigenetics
- Cancer Biology
- Molecular Therapeutics
Background:
- Pharmacological inhibitors targeting polycomb proteins aim to restore tumor suppressor gene expression but face limitations due to mutations in key transcriptional activators like TP53.
- Poor clinical outcomes of polycomb-targeting therapies in solid cancers, including triple-negative breast cancer (TNBC), hinder epigenetic monotherapy development.
Purpose of the Study:
- To develop a novel synthetic reader-actuator (SRA) for epigenome actuation by targeting polycomb chromatin.
- To investigate the SRA's ability to modulate core transcriptional activators and restore tumor suppressor gene expression in TNBC cells.
Main Methods:
- Epigenome actuation using a synthetic reader-actuator (SRA) designed to bind trimethylated histone H3 lysine 27.
- Utilizing TNBC BT-549 cells and spheroids to assess gene expression changes and phenotypic alterations.
Main Results:
- SRA expression in TNBC BT-549 cells led to a ≥2-fold upregulation of 122 genes, including those involved in cell death, cell cycle arrest, and migration inhibition.
- SRA-expressing spheroids exhibited reduced size and a loss of invasion in Matrigel, indicating inhibition of cancer cell invasiveness.
Conclusions:
- Targeting Mediator-recruiting regulators to silenced chromatin can activate tumor suppressors and promote anti-cancer phenotypes.
- Further development of robust gene regulators like the SRA may offer therapeutic benefits for patients with triple-negative breast cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
02:15Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K